🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

To all of our residents/recent grads that recently match to different fellowships, CONGRATULATIONS!!! We are proud and excited to see you achieve all your goals and dreams here UPMC 💜 or wherever else you are going for this next chapter of your lives. #Lifechangingresidency

🗓️ Join us at noon on Tuesday, 12.12.23, for the next DOM Grand Rounds! Tuesday's MGR will feature research presentations from our internal medicine residents. For the link, visit dom.pitt.edu/grandrounds/.

Another successful Medicine Grand Rounds on the books. You all make us proud and it is an absolute pleasure to witness each one of your achievements. We left today knowing more about different topics in cardiology, oncology and GI, but also left INSPIRED BY YOU. Thank you! 💜

Excited to have our abstract accepted for presentation at the upcoming #DDW2024. Thanks to my mentor Esperance Schaefer MD for the support and encouragement. Brigham and Women's GI Digestive Disease Week 🥳

Lifileucel (TIL cell therapy from Iovance Biotherapeutics) is now FDA approved for advanced PD-1 refractory melanoma!!! The melanoma community is so grateful to the patients, caregivers, and clinicians who have made the clinical trials of this therapy possible and got lifileucel to approval.

Thanks, Toni Choueiri, MD; and to the patients & study team, ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network Alliance for Clinical Trials in Oncology Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Brian Costello Amie Kim, Naomi Haas, Mike Carducci, Wayne Harris Lynne I Wagner PhD David Cella, Chris Ryan Journal of Clinical Oncology UPMC Hillman Cancer Center

Published in Journal of Clinical Oncology, Dr. Jason Luke (Jason Luke, MD, FACP) shares a three year update for the KEYNOTE-716 study. These results continue to support the use of pembrolizumab adjuvant therapy in patients with resected stage IIB or IIC melanoma. ascopubs.org/doi/10.1200/JC…

Outgoing and incoming Pitt Medicine Chiefs chief residents at #AIMW24!! So proud of these amazing humans. Pitt General Internal Medicine PittDeptofMed

"My research aims to uncover any differences in treatment outcomes among patients with pre-existing type II diabetes at the time of their metastatic melanoma diagnosis. Discovering such differences could prompt further investigation, potentially influencing recommendations

This is the face of very proud Pitt Medicine Chiefs Andy Knight, Casey Skittle, MD, MBA, Valentina Jaramillo, MD and PD Andrea Carter after witnessing the hard work and dedication of each one of our residents! We couldn’t be more honored to be here and watch all of you grow 💜 Pitt General Internal Medicine PittDeptofMed

Nice review here on recent advancements for #melanoma developmental #immunotherapy. Great work Andy Knight! Useful read as prep during your travels to #ASCO24. Bispecifics, vaccines, oncolytic virus, adoptive cell transfer, cytokines & more! rdcu.be/dI04a

Had a great time at #ASCO24 this year! Thank you to my wonderful mentors Andy Knight and John M. Kirkwood for the support and guidance with my project. And thank you to everyone who stopped by my poster. #Melanoma #Immunotherapy

Excited to share our paper out today in Cell with Tullia Bruno, PhD Vignali Lab! Part of a trio of papers, we show in #Melanoma, anti-PD1+anti-LAG3 therapy modifies CD8 differentiation to promote enhanced effector function tinyurl.com/2ap5w9va

We lost a legend today. Jeff meant so much to the fields of melanoma and immuno-oncology. We were fortunate to learn from him and share the fruits of his labor with our patients. May his memory be a blessing.

Jeffrey S Weber's life is a testament to mentorship, patient care, sacrifice, leadership. Thank you Journal for ImmunoTherapy of Cancer for allowing us to share a glimpse of this giant. jitc.bmj.com/content/12/9/e… Jason Luke, MD, FACP Bernard A Fox Moffitt Cancer Center USC Norris Comprehensive Cancer Center NYU Langone Health National Cancer Institute ASCO Melanoma Research Foundation

Check out our recent work on TLS and their overshadowed precursors, lymphoid aggregate, in melanoma out now in Journal for ImmunoTherapy of Cancer I am honored to have had the chance to study and contribute to this field under Dr. Lilit Karapetyan who has been a tremendous supporter of me all the way 🎉

Come join Dr. Vidula from MGH Breast Oncology and me for The Clinical Problem Solvers morning report!

Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in Nature Medicine! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx. nature.com/articles/s4159…

Join us tomorrow for virtual morning report!

Excellent presentation by Meghan Mooradian from ADuong presenting UPMC Hillman Cancer Center led Neo-Mel-T trial evaluating neoadjuvant anti-TIM-3+anti-PD-1 vs. neoadjuvant anti-PD-1 in high-risk resectable #melanoma. MPR 56%, 1-year RFS 87% with no surgical delays, 15%TRAE with dostar/cobo